💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pyridostigmine

CHEMBL1115 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
181.2 g/mol
LogP
0.7
Phase
4

Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

分子量

181.2100 g/mol

LogP

0.70

TPSA

33.40 Ų

リピンスキーの五則

適合

治療領域

Benign Prostatic Hyperplasia Non-Small Cell Lung Cancer Parkinson's Disease HIV/AIDS Heart Failure Leukemia

作用機序

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)C(=O)Oc1ccc[n+](C)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H13N2O2+

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
回転可能結合数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
13

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Pyridostigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1115.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4991.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.